December 15, 2003Features
The pharmaceutical industry remains cautious about computer simulation of clinical trials.
By Mark D. Uehling
Breakthroughs are making cell-based screening faster, easier, more powerful.
By Malorye A. Branca
News·Analysis Why Drugs FailFDA Guidance: More Questions Than AnswersHigh-Speed Computing: Clusters, FLOPS, CreativityC-Sixty Pitches Buckyballs for DrugsA Diagnostics Dream TeamBig Pharmas Sign Deals with GeneCardsQuick, to the GeneCave!MIT Researchers Win a GRAM(Y)Pathway PandemoniumUnbreakable vs. DisposableHorizons
Geneticist par excellence on the importance of integrated science.
Interview by Zachary Zimmerman
Impressive research budgets, pharma talent, and a prodigal son build a biotech oasis in Phoenix.
By Mark D. UehlingColumns
| Kevin Davies
FDA guidance on the road to genomic medicine.
| Michael A. Greeley
Minuscule devices promise big opportunities.
| By Robert M. Frederickson
Putting a new spin on the proteomics lab.
| By John Dodge
An ego-less model for research and innovation. Departments
Velocity11 delivers microplate systems · Biocept introduces 3-D microarrays · Accelrys ports apps to Linux